|
1
|
Johnson NB, Hayes LD, Brown K, Hoo EC and
Ethier KA: Centers for Disease Control: CDC National Health Report:
Leading Causes of Morbidity and Mortality and Associated Behavioral
Risk and Protective Factors - United States, 2005–2013. Morbidity
and Mortality Weekly Report. 63:3–27. 2014.
|
|
2
|
Kadara H, Kabbout M and Wistuba II:
Pulmonary adenocarcinoma: A renewed entity in 2011. Respirology.
17:50–65. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Biswas C, Zhang Y, Decastro R, Guo H,
Nakamura T, Kataoka H and Nabeshima K: The human tumor cell-derived
collagenase stimulatory factor (renamed EMMPRIN) is a member of the
immunoglobulin supperfamily. Cancer Res. 55:434–439.
1995.PubMed/NCBI
|
|
4
|
Kanekura T, Chen X and Kanzaki T: Basigi
(CDl47) is expressed on melanoma cells and induces tumor cell
invasion by stimulating production of matrix metalloproteinases by
fibroblasts. Int J Cancer. 99:520–528. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li R, Huang L, Guo H and Toole BP: Basigin
(murine EMMPRIN) stimulates matrix metalloproteinase production by
fibroblasts. J Cell Physiol. 186:371–379. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sameshima T, Nabeshima K, Toole BP,
Yokogami K, Okada Y, Goya T, Koono M and Wakisaka S: Glioma cell
extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147)
stimulates production of membrane-type matrix metalloproteinases
and activated gelatinase A in co-cultures with brain-derived
fibroblasts. Cancer Lett. 157:177–184. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Muramatsu T and Miyauchi T: Basigin
(CD147): A multifunctional transmembrane protein involved in
reproduction, neural function, inflammation and tumor invasion.
Histol Histopathol. 18:981–987. 2003.PubMed/NCBI
|
|
8
|
Nabeshima K, Iwasaki H, Koga K, Hojo H,
Suzumiya J and Kikuchi M: Emmprin (basigin/CD147): Matrix
metalloproteinase modulator and multifunctional cell recognition
molecule that plays a critical role in cancer progression. Pathol
Int. 56:359–367. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kanekura T and Chen X: CD147/basigin
promotes progression of malignant melanoma and other cancers. J
Dermatol Sci. 57:149–154. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen X, Lin J, Kanekura T, Su J, Lin W,
Xie H, Wu Y, Li J, Chen M and Chang J: A small interfering
CD147-targeting RNA inhibited the proliferation, invasiveness, and
metastatic activity of malignant melanoma. Cancer Res.
66:11323–11330. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hao JL, Cozzi PJ, Khatri A, Power CA and
Li Y: CD147/EMMPRIN and CD44 are potential therapeutic targets for
metastatic prostate cancer. Curr Cancer Drug Targets. 10:287–306.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen X, Kanekura T, Tsuyama S, Murata F
and Kanzaki T: Ultrastructural localization of basigin in normal
human epidermis. Histochem Cell Biol. 115:465–470. 2001.PubMed/NCBI
|
|
13
|
Chen X, Kanekura T and Kanzaki T:
Expression of basigin in human fetal, infantile and adult skin and
in basal cell carcinoma. J Cutan Pathol. 28:184–190. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yuasa J, Toyama Y, Miyauchi T, Maekawa M,
Yuasa S and Ito H: Specific localization of the basigin protein in
human testes from normal adults, normal juveniles, and patients
with azoospermia. Andrologia. 33:293–299. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Heike V, VetterKauczok CS, Schrama D,
Hofmann UB, Becker JC and Houben R: CD147 impacts angiogensis and
metastasis formation. Cancer Invest. 27:329–333. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shibuya M: Vascular endothelial growth
factor-dependent and-independent regulation of angiogenesis. BMB
Rep. 41:278–286. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ranieri G and Gasparini G: Angiogenesis
and angiogenesis inhibitors: A new potential anticancer therapeutic
strategy. Curr Drug Targets Immune Endocr Metabol Disord.
1:241–253. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kanekura T and Chen X: CD147 promotes
progression of malignant melanoma and other cancers. J Dermatol
Sci. 57:149–154. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tang J, Wu YM, Zhao P, Yang XM, Jiang JL
and Chen ZN: Overexpression of HAB18G/CD147 promotes invasion and
metastasis viaα3β1 integrin mediated FAK-paxillin and FAK-PI3K-Ca2
pathways. Cell Mol Life Sci. 65:2933–2942. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang B, Xu YF, He BS, Pan YQ, Zhang LR,
Zhu C, Qu LL and Wang SK: RNAi-mediated silencing of CD147 inhibits
tumor cell proliferation, invasion and increase chemosensitivity to
cisplatin in SGC7901 cells in vitro. J Exp Clin Cancer Res.
29:61–69. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bareschino MA, Schettino C, Rossi A,
Maione P, Sacco PC, Zeppa R and Gridelli C: Treatment of advanced
non small cell lung cancer. J Thorac Dis. 3:122–133.
2011.PubMed/NCBI
|
|
24
|
Pan Y, He B, Song G, Bao Q, Tang Z, Tian F
and Wang S: CD147 silencing via RNA interference reduces tumor cell
invasion, metastasis and increase chemosensitivity in pancreatic
cancer cells. Oncol Rep. 27:2003–2009. 2012.PubMed/NCBI
|
|
25
|
Yang X, Zhang P, Ma Q, Kong L, Li Y, Liu B
and Lei D: EMMPRIN silenceing inhibits proliferation and perineural
invasion of human salivary adenoid cystic carcinoma cells in vitro
and in vivo. Cancer Biol Ther. 13:85–91. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jain RK, Duda DG, Clark JW and Loeffler
JS: Lessons from phase III clinical trails on anti-VEGF therapy for
cancer. Nat Clin Pract Oncol. 3:24–40. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jia L, Cao J, Wei W, Wang S, Zuo Y and
Zhang J: CD147 depletion down-regulates matrix
metalloproteinase-11, vascular endothelial growth factor-A
expression and the lymphatic metastasis potential of murine
hepatocarcinoma Hca-F cells. Int J Biochem Cell Biol. 39:2135–2142.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tang Y, Nakada MT, Kesavan P, McCabe F,
Millar H, Rafferty P, Bugelski P and Yan L: Extracellular matrix
metalloproteinase inducer stimulates tumor angiogensis by elevating
vascular endothelial cell growthfactor and matrix
metalloproteinases. Cancer Res. 65:3193–3199. 2005.PubMed/NCBI
|
|
29
|
Millimaggi D, Mari M, D'Ascenzo S, Carosa
E, Jannini EA, Zucker S, Carta G, Pavan A and Dolo V: Tumor
vesicle-associated CD147 modulates the angiogenic capability of
endothelial cells. Neoplasia. 9:349–357. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Voigt H, VetterKauczok CS, Schrama D,
Hofmann UB, Becker JC and Houben R: CD147 impacts angiogensis and
metastasis formation. Cancer Invest. 27:329–333. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhong J, Ali AN, Voloschin AD, Liu Y,
Curran WJ Jr, Crocker IR and Shu HK: Bevacizumab-induced
hypertension is a predictive marker for improved outcomes in
patients with recurrent glioblastoma treated with bevacizumab.
Cancer. 121:1456–1462. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Crino L, Dansin E, Garrido P, Griesinger
F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL
and Zhou C: Safety and efficacy of first-line bevacizumab-based
therapy in advanced non-squamous non-small-cell lung cancer (SAiL,
MO19390): A phase 4 study. Lancet Oncol. 11:733–740. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Newman JR, Helman EE, Safavy S, Zhang W
and Rosenthal EL: EMMPRIN expression is required for response to
bevacizumab therapy in HNSCC xenografts. Cancer Lett. 274:313–318.
2009. View Article : Google Scholar : PubMed/NCBI
|
